妇科肿瘤免疫治疗：当前证据、生物标志物驱动实践及未来方向

Immunotherapy in Gynecologic Cancers: Current Evidence, Biomarker-Driven Practice, and Future Directions.

WNK4 通过重编程巨噬细胞向 M1 样表型极化抑制子宫内膜癌进展

WNK4 restrains endometrial cancer progression by reprogramming macrophage polarization toward an M1-like phenotype.

WNK4 在子宫内膜癌中作为免疫相关抑制因子，部分通过限制 M2 样极化和削弱巨噬细胞驱动的肿瘤支持发挥作用。

探索子宫内膜异位症相关菌群失调在子宫内膜癌发生中的可能作用

Exploring the Possible Role of Endometriosis-Associated Dysbiosis in Endometrial Carcinogenesis.

NK 细胞在子宫内膜癌肿瘤免疫逃逸与免疫治疗耐药交界处的作用

Natural killer cells at the interface of tumor immune escape and immunotherapy resistance in endometrial cancer.

错配修复缺陷与子宫内膜癌组织病理学参数的关联：一项来自伊拉克库尔德斯坦地区的研究

The association of mismatch repair deficiency with histopathological parameters in endometrial carcinoma: A study from the kurdistan region of Iraq.

MMRd 以 MLH1/PMS2 缺失模式为主，与子宫内膜样组织学类型、肿瘤分级和 TIL（肿瘤浸润淋巴细胞）显著相关。MMRd 可作为有用的分子生物标志物和免疫微环境的潜在预测因子，支持其在预后和个体化治疗中的作用。

间充质干细胞和 NK 细胞来源的细胞外囊泡对子宫内膜癌细胞顺铂反应性的差异效应

Differential Effects of Mesenchymal Stem Cell- and Natural Killer Cell-Derived Extracellular Vesicles on Cisplatin Responsiveness in Endometrial Cance

妇科恶性肿瘤中的免疫异质性与治疗耐药性

Immune heterogeneity and therapeutic resistance in gynecological malignancies.

妇科肿瘤的免疫治疗：从机制到临床实践

Immunotherapy for gynecological tumors: From mechanism to clinical practice.

多组学分析将 DNA2 定位在泛癌中基因组完整性程序与肿瘤行为的交界处

Multi-omics analysis positions DNA2 at the interface of genome integrity programs and tumor behavior in pan-cancer.

ROBO1 CAR-NK92 细胞中 Cbl-b 敲除增强其抗肿瘤疗效

Ablation of Cbl-b in ROBO1 CAR-NK92 Cells Enhances Their Antitumor Efficacy.